Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10278923 Oral dosing of GLP-1 compounds

Patent 10278923 was granted and assigned to Novo Nordisk on May, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Flemming S. Nielsen0

Per Sauerberg0

Date of Patent

May 7, 2019

Patent Application Number

15651043

Date Filed

July 17, 2017

Patent Citations Received

US Patent 11833248 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

0

US Patent 11034746 Double-acylated GLP-1 derivatives

0

US Patent 11759503 Compositions of GLP-1 peptides and preparation thereof

US Patent 11759502 Compositions of GLP-1 peptides and preparation thereof

US Patent 11759501 Compositions of GLP-1 peptides and preparation thereof

US Patent 11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

0

US Patent 10933120 Compositions of GLP-1 peptides and preparation thereof

US Patent 10960052 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid

...

Patent Primary Examiner

Shulamith H. Shafer

Patent abstract

The present invention relates to improved uses of GLP-1 peptides in oral therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10278923 Oral dosing of GLP-1 compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.